Bleeding disorder is a set of disorders, or disease which normally affect the process of clotting of our blood. This bleeding can be in many cases like during an accident, trauma condition, surgery, injury or a menstrual cycle. These bleeding disorders are not only associated with bloods leaving out from our body, rather it can also be an internal bleeding beneath our skin or brain. These may be hemophilia A and B or Willebrand’s disease for example. Sometimes this disease is also termed as royal disease.
The main symptom of bleeding disorder would be excessive bleeding and prolonged clotting time during normal injuries also. These can also easily identified by frequent nose bleeding, heavy menstrual bleeding and unexplained bruishing.
There are mainly two common type of instant treatment available for bleeding disorder, which is iron supplementation or clotting factor repalacement and blood transfusion. These are the therapeutic aspect, but extended research is in progress in various countries, where this disease has a greater prevalence rate.
The best known and most common bleeding disorders are Haemophilia A (Factor VIII deficiency), Haemophilia B (Factor IX deficiency) and von Willebrand Disease. However, these do not represent all bleeding disorders. There are a large number of rarer bleeding disorders both of coagulation factors and of platelets. This publication deals with nine disorders affecting coagulation factors I, II, V, VII, X, XI and XIII, in addition to two disorders affecting platelets. Generally the prevalence of these rarer bleedings disorders varies from 1: 100,000 (Factor XI deficiency) to 1: 3 million (Factor XIII deficiency). The prevelance of many of these rare bleeding disorders is higher in Ireland. The reasons for this are not clear, but a small gene pool of large family sizes in the past may be contributory factors. At the time of production of this booklet, there are 443 people with rare bleeding disorders registered with the National Centre for Hereditary Coagulation Disorders in Ireland.
Translational tools as applicable to autoimmune disorders: antibody-proteases as a generation of highly informative and unique biomarkers to monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS) PPT Version |